Switzerland· 69481002
Tepkinly 48 mg/0,8 ml, Injektionslösung
A epcoritamab product containing epcoritamabum, registered in Switzerland by AbbVie AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Epcoritamab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FX27 (epcoritamab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Epcoritamab · ATC L01FX27
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of epcoritamab costs, country by country.
Normalised to the WHO defined daily dose (1.7 mg), so markets compare like for like.
- Switzerland: $281.38 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Epcoritamab · price per daily dose (1.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$281.38
The record
At a glance
Swissmedic (Switzerland)- Active substance
- epcoritamabum
- Manufacturer
- AbbVie AG
- Country
- Switzerland (CH)
- ATC code
- L01FX27
- ATC class
- Epcoritamab
- Defined daily dose
- 1.7 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806948100291 StkCHF 6588.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Epcoritamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEPKINLYGenmab US, Inc.
- CanadaEPKINLYABBVIE CORPORATION
- CzechiaTEPKINLYAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainTEPKINLY 4 MG/0,8 ML SOLUCION INYECTABLEAbbvie Deutschland Gmbh & Co. Kg
- FinlandTepkinlyAbbVie Deutschland GmbH&Co.KG
- FranceTEPKINLY 4 mg/0,8 mL, solution injectableABBVIE DEUTSCHLAND (ALLEMAGNE)
- United KingdomTepkinly 48mg/0.8ml solution for injection vialsAbbVie Ltd
- BelgiumTepkinly 4 mg/0.8 mlAbbVie Deutschland
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Tepkinly
- Iceland · Tepkinly
- Liechtenstein · Tepkinly
- Norway · Tepkinly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd25c42c-6293-4934-bbc0-d840bd2b6e2a GET /v1/drugs/cd25c42c-6293-4934-bbc0-d840bd2b6e2a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "epcoritamabum 48 mg",
"valid_from": "2026-08-01",
"limitations": "[{\"description\":\"Nach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorheriger Konsultation des Vertrauensarztes.<br>\\nTEPKINLY wird vergütet als Monotherapie zur Behandlung von erwachsenen Patienten mit einem rezidivierenden oder refraktären diffusen grosszelligen B‐Zell-Lymphom (diffuse large B-cell lymphoma, DLBCL) nach zwei oder mehr systemischen Therapielinien, einschliesslich eines CD20-gerichteten Antikörpers,<br>\\n- welche für eine anti-CD19-gerichtete CAR-T-Zelltherapie nicht in Frage kommen oder diese bereits erhalten haben UND<br>\\n- bei denen keine ZNS-Beteiligung des Lymphoms vorliegt.<br>\\nDie Behandlung mit TEPKINLY wird vergütet, bis eine Krankheitsprogression oder inakzeptable Toxizität auftritt.<br>\\n<br>\\nFür TEPKINLY bestehen Preismodelle. Die Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin, für jede bezogene Packung TEPKINLY einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Indikationscode ist an den Krankenversicherer zu übermitteln: 21741.01<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21741.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-12-01\",\"validTo\":\"2027-04-30\"}]",
"galenic_form": "Inj Lös 48 mg/0.8 ml Durchstf",
"therapeutic_area": null,
"sl_inclusion_date": "2025-12-01",
"self_retention_pct": 10
}See everything about epcoritamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.